Hepatocellular carcinoma patients with high circulating cytotoxic T cells and intra-tumoral immune signature benefit from pembrolizumab: results from a single-arm phase 2 trial

Table 1 Baseline characteristic of patients

		n = 60 (%)
Age	< 60	28 (46.7%)
Age	≥ 60	32 (53.3%)
Sex	Female	12 (20.0%)
Sex	Male	48 (80.0%)
ECOG performance status	0	9 (15.0%)
ECOG performance status	1	51 (85.0%)
Pathologic confirmation	No	0 (0.0%)
Pathologic confirmation	Yes	60 (100%)
Child-Pugh classification	A5	41 (68.3%)
Child-Pugh classification	A6	19 (31.7%)
Etiology	Hepatitis B	46 (76.7%)
	Hepatitis C	6 (10.0%)
	Alcohol	1 (1.7%)
	Primary biliary cirrhosis	1 (1.7%)
	Others	6 (10.0%)
Alpha-fetoprotein	≥ 400	30 (50.0%)
Alpha-fetoprotein	< 400	30 (50.0%)
Extrahepatic disease	No	8 (13.3%)
Extrahepatic disease	Yes	52 (86.7%)
Prior treatment	Transplantation	0 (0.0%)
	Surgery	17 (28.3%)
	Locoregional therapy (RFA, TACE)	41 (68.3%)
	Radiotherapy	31 (51.7%)
Prior chemotherapy	1	48 (80.0%)
Prior chemotherapy	≥ 2	12 (20.0%)
Prior sorafenib	No	0 (0.0%)
Prior sorafenib	Yes	60 (100%)

ECOG, Eastern Cooperative Oncology Group; RFA, radiofrequency ablation; TACE, transarterial chemoembolization

ISSN: 1756-994X